Announced Tue, 16 Jun · 09:25 IST
Suven Life Sciences completes Phase-1 trial of SUVN-I6107, advances to Phase-2
Compliance View source PDF
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹270.20
prior close
₹260.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.3+1.7+1.5+0.9-1.9-4.0-1.0-2.5-4.4-1.0+17.7+26.2——
Up moveDown movePending
AI summary
Suven Life Sciences completed Phase-1 first-in-human study of SUVN-I6107, a M1 positive allosteric modulator (M1-PAM) for CNS disorders. The study enrolled 40 participants in SAD and 24 in MAD cohorts. Results showed favorable safety with no SAEs, predictable pharmacokinetics (half-life ~7-11 hours), no significant sex or food effects, and biomarker evidence of CNS activity. Drug is advancing to Phase-2.
Likely market impact
Positive clinical milestone; Phase-1 success supports pipeline advancement, likely boosting investor sentiment on the CNS franchise.